| Filed On | Filing |
|---|---|
| 28 Aug 2026 |
8-K: Departure/Election of Directors or Officers; Compensation
This Consulting Agreement (the “Agreement”) is made effective as of September 1, 2026 (the “Effective Date”), by and between Vyome Holdings, Inc., a Delaware corporation, with its principal place of business at Harvard Square, One Miffli... |
| 25 Aug 2026 |
8-K: Results of Operations and Financial Condition
Vyome Holdings Reports Second Quarter 2026 Results Highlighted By Advancement Of Lead VT-1953 Program, Pipeline Expansion And Strong Balance Sheet |
| 29 May 2026 |
8-K: Results of Operations and Financial Condition
Vyome has signed an agreement with Impetis Biosciences Limited, a TATA Enterprise, to in-license two selective JAK inhibitor assets, opening access to a large and growing ~$57B global market1 |
| 29 Apr 2026 |
8-K: Amendments to Articles/Bylaws; Change in Fiscal Year; Submission of Matters to a Vote of Security Holders
I, CHARUNI PATIBANDA-SANCHEZ, SECRETARY OF STATE OF THE STATE OF DELAWARE, DO HEREBY CERTIFY THE ATTACHED IS A TRUE AND CORRECT COPY OF THE RESTATED CERTIFICATE OF “VYOME HOLDINGS, INC.”, FILED IN THIS OFFICE ON THE TWENTY-FOURTH DAY OF ... |
| 25 Feb 2026 |
8-K: Entry into a Material Definitive Agreement; Other Events
This Notes Purchase and Exchange Agreement (this “Agreement”) is entered into as of February 20, 2026 (the “Effective Date”) by and among (i) LiveChain, Inc., a Nevada corporation (“LICH”); (ii) LICH AI, Inc., a Delaware corporation and ... |
| 13 Feb 2026 |
8-K: Regulation FD Disclosure
VT - 1953 in Treating Symptoms of Malignant Fungating Wounds (MFW) PHASE 2 IST STUDY RESULTS & NEXT STEPS © Vyome Holdings, Inc. February 2026 |
| 28 Jan 2026 |
8-K: Regulation FD Disclosure; Other Events
1 U.S. Market & Product Assessment and Valuation of VT - 1953 for the Treatment of Symptoms of Malignant Fungating Wounds H1 2026 |
| 23 Dec 2025 |
8-K: Entry into a Material Definitive Agreement
This letter of intent (this “LOI”) outlines the general terms and conditions of a prospective transaction (as further described herein, the “Transaction”) between LiveChain, Inc., a Delaware corporation (“LICH”), Remus Capital Series B I... |
| 19 Nov 2025 |
8-K: Results of Operations and Financial Condition
Completed a streamlined Nasdaq listing, with a 100% common stock capital structure |
| 30 Oct 2025 |
8-K: Submission of Matters to a Vote of Security Holders
On October 28, 2025, Vyome Holdings, Inc. (the “Company”) held its 2025 Annual Meeting of Stockholders. A total of 4,258,856 shares of common stock representing 77.52% of the aggregate shares outstanding and eligible to vote and constitu... |
| 03 Oct 2025 |
8-K: Other Events
Launches business unit to create AI psychiatrist focused on reducing inflammation |
| 02 Sep 2025 |
8-K: Other Events
The accompanying notes are an integral part of these consolidated financial statements. |
| 20 Aug 2025 |
8-K: Entry into a Material Definitive Agreement; Changes in Registrant's Certifying Accountant
This AMENDMENT NO. 1 TO EQUITY DISTRIBUTION AGREEMENT (this “Amendment”) is entered into as of August 20, 2025, by and between Vyome Holdings, Inc. (formerly known as ReShape Lifesciences, Inc.), a Delaware corporation (the “Company”), a... |
| 19 Aug 2025 |
8-K: Completion of Acquisition or Disposition of Assets; Unregistered Sales of Equity Securities +3 more
I, CHARUNI PATIBANDA-SANCHEZ, SECRETARY OF STATE OF THE STATE OF DELAWARE, DO HEREBY CERTIFY THE ATTACHED IS A TRUE AND CORRECT COPY OF THE CERTIFICATE OF DESIGNATION OF “RESHAPE LIFESCIENCES INC.”, FILED IN THIS OFFICE ON THE FOURTEENTH... |
| 11 Aug 2025 |
8-K: Submission of Matters to a Vote of Security Holders
On August 7, 2025, ReShape Lifesciences Inc. (the “Company”) reconvened its special meeting of stockholders (“Special Meeting”), which was partially adjourned on July 24, 2025. |
| 25 Jul 2025 |
8-K: Submission of Matters to a Vote of Security Holders
ReShape Lifesciences Inc. (the “Company”) held a special meeting of stockholders on July 24, 2025 (the “Special Meeting”). A total of 1,482,585 shares of the Company’s common stock, par value $0.001 per share (the “Common Stock”), consti... |
| 15 Jul 2025 |
8-K: Regulation FD Disclosure
Vyome A US-India healthcare platform with clinical-stage immuno-inflammation assets PENDING MERGER $RSLS TO $HIND CORPORATE PRESENTATION JULY 2025 |
| 03 Jul 2025 |
8-K: Entry into a Material Definitive Agreement
FOR VALUE RECEIVED, Vyome Therapeutics, Inc., a Delaware corporation (“Vyome”), promises to pay to the order of ReShape Lifesciences Inc., a Delaware corporation and its successors and assigns (“ReShape”), in lawful money of the United S... |
| 18 Jun 2025 |
8-K: Other Events
As previously disclosed, on May 28, 2025, ReShape Lifesciences Inc. (the “Company”) received a written notice from the Listing Qualifications Department of The Nasdaq Stock Market LLC notifying the Company its securities are subject to d... |
| 12 Jun 2025 |
8-K: Entry into a Material Definitive Agreement; Regulation FD Disclosure
Subject to the terms and conditions herein (this “Agreement”), ReShape Lifesciences Inc., a Delaware corporation (including any successor thereto, the “Company”), hereby agrees to sell up to an aggregate of $2,636,510 of shares (each a "... |
Loading...